newsfilter
← Latest News
GlobeNewswire·

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Boston (March 13, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt